Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the trea…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
This week | ||
RBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview Nuvation Bio Inc. (NYSE:NUVB) is one of the best small cap stocks to buy with the highest upside potential. RBC Capital lowered the price target on Nuvation Bio Inc. (NYSE:NUVB) to $19 from $20 on July 7 and reaffirmed an Outperform rating on the shares. The rating update came as part of a broader research note […] | ||
Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level? Nuvation Bio Inc (NYSE:NUVB) is one of billionaire David Abrams’ top stock picks with upside potential. Nuvation Bio shares gained nearly 170% over the past year, and analysts project a more than 150% upside for the stock over the next 12 months. Some 41 hedge funds are backing Nuvation Bio stock. This comes as Nuvation […] | ||
Older | ||